LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

Search

Charles River Laboratories International Inc

Fechado

SetorSaúde

164.83 -0.37

Visão Geral

Variação de preço das ações

24h

Atual

Mín

163

Máximo

167.86

Indicadores-chave

By Trading Economics

Rendimento

-332M

-277M

Vendas

-11M

994M

EPS

2.43

Margem de lucro

-27.816

Funcionários

18,300

EBITDA

730K

198M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+24.11% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-163M

7.8B

Abertura anterior

165.2

Fecho anterior

164.83

Sentimento de Notícias

By Acuity

12%

88%

15 / 349 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Charles River Laboratories International Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

26 de mar. de 2026, 23:43 UTC

Conversa de Mercado

Nikkei May Decline Amid Uncertainty Over Iran Peace Talks -- Market Talk

26 de mar. de 2026, 23:36 UTC

Conversa de Mercado
Notícias Principais

Gold Rises Amid Signs of Easing Middle East Tensions -- Market Talk

26 de mar. de 2026, 23:35 UTC

Aquisições, Fusões, Aquisições de Empresas

Pernod Ricard: Confirms Discussions With Brown-Forman

26 de mar. de 2026, 23:29 UTC

Ganhos

Haier Smart Home: Company to Finance Share Buybacks Via Internal Funds >600690.SH

26 de mar. de 2026, 23:28 UTC

Ganhos

Haier Smart Home Plans A Share Buybacks of CNY3.0B-CNY6.0B >600690.SH

26 de mar. de 2026, 23:28 UTC

Ganhos

Haier Smart Home Plans to Increase Payout Ratio to 60% for 2027, 2028 >600690.SH

26 de mar. de 2026, 23:28 UTC

Ganhos

Haier Smart Home Plans Cash Dividend Payout Ratio of Up to 58% for 2026 >600690.SH

26 de mar. de 2026, 23:27 UTC

Ganhos

Haier Smart Home 2025 Net CNY19.55B Vs. Net CNY18.73B >600690.SH

26 de mar. de 2026, 23:27 UTC

Ganhos

Haier Smart Home 2025 Rev CNY302.33B Vs. CNY286.01B >600690.SH

26 de mar. de 2026, 23:08 UTC

Conversa de Mercado

Infratil's Investor Day Addresses Data-Center Issues -- Market Talk

26 de mar. de 2026, 23:04 UTC

Aquisições, Fusões, Aquisições de Empresas

Pernod Ricard in Talks to Combine With Jack Daniel's Maker Brown-Forman -- WSJ

26 de mar. de 2026, 23:04 UTC

Aquisições, Fusões, Aquisições de Empresas

Families Behind Pernod, Brown-Forman Would Each Likely Retain Significant Stakes, Source Says -- WSJ

26 de mar. de 2026, 23:04 UTC

Aquisições, Fusões, Aquisições de Empresas

Pernod, Brown-Forman Discussing Mostly Stock Deal, Source Says -- WSJ

26 de mar. de 2026, 23:04 UTC

Aquisições, Fusões, Aquisições de Empresas

Pernod-Brown-Forman Deal Announcement Could Be Weeks Away, Sources Say -- WSJ

26 de mar. de 2026, 23:04 UTC

Aquisições, Fusões, Aquisições de Empresas

Pernod in Deal Talks With Brown-Forman -- WSJ

26 de mar. de 2026, 22:41 UTC

Aquisições, Fusões, Aquisições de Empresas

Brown-Forman: No Agreement Has Been Reached as to Terms of Any Possible Pernod Ricard Transaction

26 de mar. de 2026, 22:41 UTC

Aquisições, Fusões, Aquisições de Empresas

Brown-Forman: Synergies From Contemplated Pernod Ricard Combination Expected to Be Significant

26 de mar. de 2026, 22:26 UTC

Ganhos

Jiangxi Copper 2025 Rev CNY544.62B Vs. CNY516.61B >0358.HK

26 de mar. de 2026, 22:26 UTC

Ganhos

Jiangxi Copper 2025 Net CNY7.13B Vs. Net CNY6.96B >0358.HK

26 de mar. de 2026, 22:26 UTC

Ganhos

Jiangxi Copper Higher Demand For Products Supported Results>0358.HK

26 de mar. de 2026, 22:08 UTC

Ganhos

Air China 2025 Loss CNY1.79B Vs. Loss CNY232.56M >0753.HK

26 de mar. de 2026, 22:08 UTC

Ganhos

Air China Impairment Loss on Goodwill Weighed on Results>0753.HK

26 de mar. de 2026, 22:08 UTC

Ganhos

Air China 2025 Rev CNY171.48B Vs. CNY166.70B >0753.HK

26 de mar. de 2026, 22:07 UTC

Conversa de Mercado
Notícias Principais

Global Energy Roundup: Market Talk

26 de mar. de 2026, 22:07 UTC

Conversa de Mercado
Notícias Principais

Open-Pit Gold Miners Most Exposed to High Fuel Prices -- Market Talk

26 de mar. de 2026, 22:00 UTC

Ganhos

Tsingtao Brewery 2025 Net CNY4.59B Vs. Net CNY4.34B >0168.HK

26 de mar. de 2026, 22:00 UTC

Ganhos

Tsingtao Brewery: Higher Volume Sales of Beer Supported Results>0168.HK

26 de mar. de 2026, 22:00 UTC

Ganhos

Tsingtao Brewery 2025 Rev CNY32.47B Vs. CNY32.14B >0168.HK

26 de mar. de 2026, 21:39 UTC

Aquisições, Fusões, Aquisições de Empresas

BlueScope: Sees Early Indications of Strong Interest in Site Adjacent Western Port

26 de mar. de 2026, 21:38 UTC

Aquisições, Fusões, Aquisições de Empresas

BlueScope: Has Begun Expression of Interest Process For 65-Hectare Site Adjacent Western Port

Comparação entre Pares

Variação de preço

Charles River Laboratories International Inc Previsão

Preço-alvo

By TipRanks

24.11% parte superior

Previsão para 12 meses

Média 205.89 USD  24.11%

Máximo 265 USD

Mínimo 175 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

8

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

117.16 / 144.77Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

15 / 349 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat